Using a Nobel Prize-winning technique called cryo-EM, researchers were able to identify potential areas on the hepatitis C virus that a vaccine could target.
Academic rigor, journalistic flair
Articles on Hepatitis C
Displaying 1 - 20 of 58 articles
There has been a monumental policy shift in paying blood plasma donors in Canada.
Millions of Americans wear jewelry that pierces the ear, nose, lips, tongue and genital areas. But adorning yourself with metal body art can be a health hazard.
Direct-acting antivirals can cure hepatitis C in eight to 12 weeks. But while the rate of uptake in Australia has slowed, a greater proportion of those undertaking treatment are in prison.
Some cancers are actually caused by viruses that linger for long periods in the body, or cause physical damage that later turns cancerous.
CC BY-NC-ND10.5 MB (download)
New direct-acting antiviral drugs would work successfully in countries where numerous different strains of hepatitis C are found.
Direct-acting antivirals have mostly been used in countries with high incomes. These drugs would be effective against most hepatitis C strains. which are primarily low-income countries.
Michael Houghton, an Edmonton-based virologist, was one of the recipients of this year’s Nobel Prize for physiology or medicine for the discovery of hepatitis C.
The 2020 Nobel Prize for Physiology or Medicine goes to the discoverers of the hepatitis C virus. There’s an effective cure but homelessness and the opioid epidemic are driving a surge in infections.
About 19 million Nigerians have hepatitis but most of them don’t know it.
Proposals in NSW to force someone who spits at or bites a frontline worker to be tested for HIV and other blood-borne viruses are a real problem - for workers and the public.
New research reveals a link between a diagnosis of cancer and a lifetime number of 10 or more sexual partners. But there are some flaws in the research we need to consider in interpreting the results.
Curing thousands of Australians with hepatitis C is one of the public health success stories of recent years. We can take lessons from this as we continue in the fight against hepatitis B.
A new test which capitalises on existing knowledge and technology will increase diagnoses, speed up the process and save the NHS millions of pounds.
As concern grows for the escalating prices of prescription drugs, a novel approach to lower the price of drugs to treat hepatitis C in Louisiana holds promise, a policy expert says.
A better understanding of CFS could lead to new treatments.
Somewhere along our evolutionary path, we lost the ability to defend against hepatitis C. But not all humans lost this ability.
July 28 is World Hepatitis Day, and with an effective cure for hepatitis C there is much to celebrate. But homelessness and the opioid epidemic are driving a surge in hepatitis infections.
To prevent the epidemic of liver cancer that looms on the horizon, we need to tackle hepatitis B, hepatitis C and obesity.
In the run up to the Global Hepatitis Summit 2018, new guidelines for the management of hepatitis C should come under scrutiny – for financial conflict of interest and quality of evidence.
Top contributors
-
Infectious Diseases Physician, St Vincent's Hospital, Sydney; Scientia Professor, Kirby Institute, UNSW Sydney
-
Director, WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity
-
Professor of Viral Hepatitis, University of Glasgow
-
Emeritus Consultant, St Vincent's Hospital, Darlinghurst
-
Deputy Director, Burnet Institute, Adjunct Professor, Monash University, Burnet Institute
-
Research Fellow, Australian Research Centre in Sex, Health and Society, La Trobe University
-
Associate Professor of Epidemiology & Program Head of Surveillance Evaluation and Research, UNSW Sydney
-
Professor and Director of the Centre for Social Research in Health, UNSW Sydney
-
Professor of Internal Medicine, University of Michigan
-
Associate Professor, University of Sydney
-
Associate professor, La Trobe University
-
Adjunct Professor, La Trobe University
-
Professor and Executive Dean of School, Medical and Health Sciences, Edith Cowan University
-
Associate Professor and Head of the Surveillance and Evaluation Program for Public Health at the Kirby Institute, UNSW Sydney
-
Adjunct Professor, School of Psychology, Curtin University and College of Health and Medicine, Australian National University
